Navigation Links
Janet Rowley, MD, A Researcher Funded by The Leukemia & Lymphoma Society, Receives Presidential Medal of Freedom
Date:7/30/2009

WHITE PLAINS, N.Y., July 30 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) congratulates Janet Davis Rowley, M.D., of University of Chicago, a pioneer in demonstrating that cancer is a genetic disease, for being awarded the 2009 Presidential Medal of Freedom. President Barack Obama will award the Medals of Freedom, the nation's highest civilian honor, to Rowley and 15 others at a ceremony Aug. 12, 2009.

Dr. Rowley is being recognized for her discoveries of recurring chromosomal abnormalities in leukemias and lymphomas -- findings that have revolutionized how cancer is understood and treated. Since 1984, LLS has awarded Dr. Rowley's lab eight grants, including the current Translational Research Program (TRP) grant, effective through 2011. The current funding is supporting her work developing a tool to more precisely diagnose genetic subtypes of acute myelogenous leukemia (AML) so that more appropriate individualized treatment can be applied to patients.

Dr. Rowley's earlier work helped to establish that cancer is a genetic disease, demonstrating that mutations in critical genes lead to specific forms of leukemia and lymphoma. Her discoveries helped lay the groundwork for the development of targeted and individualized therapy for patients with cancer. In 1973, Dr. Rowley showed that the Philadelphia Chromosome associated with chronic myelogenous leukemia (CML) was an abnormal translocation of two chromosomes. Her discovery was a key step in the eventual discovery of Gleevec, a targeted therapy for CML patients.

Rowley, 84, is the Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics and Cell Biology and Human Genetics at the University of Chicago.

"Dr. Rowley's work during her exemplary career has had a major impact on the treatment and on the lives of patients with leukemia," said John Walter, LLS president and CEO. "LLS is extre
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines
2. Working Mother Magazine Names Janet Liang Working Mother of the Year
3. Lynchburg, VA Dermatologist Janet G. Hickman, MD Honored With Rose Hirschler Award from Womens Dermatologic Society
4. Researchers Discover the Tale Behind Short Dogs
5. Higher drug doses needed to defeat tuberculosis, UT Southwestern researchers report
6. Mayo researchers find anesthesia not harmful for babies during birth process
7. Mayo Researchers Find Anesthesia Not Harmful for Babies During Birth Process
8. Pinpointing cause of colic: UT Houston researchers identify organism
9. Life after chemotherapy: Daily tasks, quality of life may be affected, MU researcher finds
10. Zucker Hillside Researchers to Receive Large Federal Grant to Test for the Early Treatment of Schizophrenia
11. Researchers find that eating high levels of fructose impairs memory in rats
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 1VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 2VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 4Colorectal cancer 9090 1Genetically engineered mice yield clues to knocking out cancer 9086 1Genetically engineered mice yield clues to knocking out cancer 9086 2